B-lymphoblastic leukemia/lymphoma MLL rearranged

Summary

B-lymphoblastic leukemia/lymphoma MLL rearranged (MONDO:0850156) is a cancer. A subtype of B-cell acute lymphoblastic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	B-lymphoblastic leukemia/lymphoma MLL rearranged
Mondo ID	MONDO:0850156
DOID	DOID:0080644
GARD	0026583
Is cancer (heuristic)	yes

Disease family

This is a subtype of B-cell acute lymphoblastic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › acute lymphoblastic leukemia › B-cell acute lymphoblastic leukemia › B-lymphoblastic leukemia/lymphoma MLL rearranged

Related subtypes (15): B-cell acute lymphoblastic leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1), B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1, B-lymphoblastic leukemia/lymphoma with IL3-IGH, B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like, B-lymphoblastic leukemia/lymphoma with IAMP21, B-lymphoblastic leukemia/lymphoma with t(7;9)(q11.2;p13.2), B-lymphoblastic leukemia/lymphoma with t(17;19), B acute lymphoblastic leukemia with PAX5 P80R mutation, B acute lymphoblastic leukemia with DUX4 rearrangement, B-lymphoblastic leukemia with MEF2D rearrangement, B-lymphoblastic leukemia with MYC rearrangement, B-lymphoblastic leukemia with NUTM1 rearrangement, B-lymphoblastic leukemia with PAX5alt, B-lymphoblastic leukemia with TCF3-HLF fusion, B-lymphoblastic leukemia with ZNF384 rearrangement

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.